Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura

Rituximab is a chimeric monoclonal antibody that specifically targets the CD20 molecule on the B cell surface. Although rituximab was originally introduced for the treatment of lymphoid neoplasms such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), it is now emerging as an effective and relatively safe therapeutic option for the patients with refractory immune thrombocytopenic purpura (ITP). We report here on a case of life-threatening toxic epidermal necrolysis (TEN) that was related with the use of rituximab in a patient with refractory ITP. The patient developed extensive erythematous papules and bullous lesions on his whole body associated with fever and visual disturbance during the second cycle of rituximab. The rituximab was discontinued and high dose intravenous immunoglobuline and steroid were administrated. Four weeks later, he fully recovered without any sequelae. A review of the literature reveals this to be the first reported case of TEN associated with rituximab injection in Korea.

A Case of Recurrence after Endoscopic Submucosal Dissection of Esophageal Adenocarcinoma Arising from Barrett's Esophagus / 대한소화기내시경학회지

Surgery is the primary treatment for adenocarcinoma arising from Barrett's esophagus. However, in order to avoid the high risk of complications of surgical resection, many physicians try various endoscopic treatments in cases of early adenocarcinoma and high-grade dysplasia of Barrett's esophagus. Endoscopic submucosal dissection (ESD) is a recently highlighted technique because of its high rate of en bloc resection, but there is controversy about ESD because of the uncertain long-term effect. There is a high risk of local recurrence after endoscopic treatments especially in a long-segment Barrett's esophagus, but there are no reports about this in Korea. This case we report on shows that the early adenocarcinoma arising from a long-segment Barrett's esophagus was curatively removed by ESD, but recurred high-grade dysplasia was detected on the remnant Barrett's esophagus after one year. We report here on a case of recurred esophageal malignancy after successful endoscopic resection of adenocarcinoma from a Barrett's esophagus.